Vaxzevria approved in the EU as third dose booster against Covid-19
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Quantib Prostate is an AI-based software solution that advances the MRI prostate reporting workflow and is accessible directly from the radiologist's reading station
In clinical trials, treatment proved more effective than other therapies evaluated
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
Revolutionary ovarian cancer rapid test available Q4 2022
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes – detecting four infections simultaneously
While Pregabalin will be manufactured at the Aurangabad facility, Iloperidone will be manufactured at the Goa facility
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Subscribe To Our Newsletter & Stay Updated